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Introduction {#sec1}
============

The omentum, a visceral fat depot contained within a fold of peritoneum, has the capacity to rapidly absorb particles and pathogens present in the peritoneal cavity ([@bib33], [@bib42]). The omentum has important immunological properties derived from the presence of numerous immune cell clusters called fat-associated lymphoid clusters (FALCs; [@bib44]), which are also found in the mesentery ([@bib36]), the mediastinum, and pericardium, in association with the peritoneal, pleural, and pericardial cavities ([@bib4], [@bib20]). The continuous flow of fluid from the peritoneal cavity through omental (om)FALCs makes them unique niches for the clearance of peritoneal contaminants and initiation of protective immune responses during peritonitis.

FALCs support multifaceted stromal-immune cell interactions, which are critical for the maintenance and function of innate-like B cells (IBCs) within the serous cavities, as well as facilitating T-cell-dependent B cell immune responses to peritoneal antigens ([@bib2], [@bib4], [@bib44]). FALC stromal cells produce the chemokine CXCL13, which maintains peritoneal IBCs ([@bib2], [@bib4], [@bib44]). Upon inflammatory signals, serous B cells migrate into FALCs where the provision of interleukin (IL)-5 by type 2 innate lymphocytes (ILC2s) causes rapid B cell proliferation and IgM secretion ([@bib19], [@bib20]). FALC stromal cells produce IL-33 ([@bib20]), which induces IL-5 secretion by ILC2s ([@bib36]). Peritonitis induces *de novo* FALC formation that is dependent on the production of tumor necrosis factor (TNF) by monocytes and/or macrophages, and TNF receptor (TNFR) signaling in stromal cells ([@bib4]). The initial recruitment of inflammatory monocytes into FALCs requires MYD88 dependent activation of *Ccl19*-expressing FALC stromal cells ([@bib41]). The cross-talk between monocytes and FALC stromal cells supports B cell differentiation ([@bib41]) and FALC expansion ([@bib4]).

FALCs are highly vascularized ([@bib12], [@bib33]) and act as gateways to the peritoneal cavity during peritonitis. During TNF-induced peritonitis, neutrophils rapidly transit through the high endothelial venules (HEVs) of omFALCs to enter the peritoneal cavity ([@bib9]). The extravasation of cells into the peritoneal cavity via FALCs may be facilitated by the presence of a loose lining of mesothelial cells ([@bib14], [@bib17]).

The ability of the omentum to collect peritoneal contaminants is attributed to the flow of fluid from the peritoneal cavity through the omentum, with omFALCs acting as an integrated filtration system. Here, we investigated the mechanisms enabling the capture of peritoneal contaminants by FALCs by first defining the contribution of stromal-immune cell interactions to the capture and neutralization of contaminants. Single-cell RNA sequencing (scRNA-seq) revealed heterogeneity within the stomal compartment and defined two populations of mesothelial-derived stromal cells. Three-dimensional reconstruction of FALC stromal architecture showed that mesothelial-derived stromal cells covered the surface of omFALCs. These cells produced immune mediators including the neutrophil recruitment chemokine, CXCL1. CXCL1 was critical for the retention and accumulation of neutrophils in omFALCs during Zymosan-induced peritonitis. Neutrophil aggregates at omFALCs were coated with neutrophil extracellular trap (NET)-like DNA structures that concentrated Zymosan particles. *In vivo* chemical inhibition of protein arginine deiminase 4 (PAD4), an enzyme important for NET formation, abolished neutrophil aggregation at omFALCs and resulted in increased dissemination of peritoneal contaminants to the spleen. Similar NET-like DNA structures were detected within the omentum of patients with acute appendicitis. Thus, stromal cells within omFALCs coordinate the neutrophil response to restrict peritoneal contaminants. Manipulating this pathway may provide therapeutic avenues for the treatment of peritonitis.

Results {#sec2}
=======

scRNA-Seq Reveals the Presence of Three Distinct Omental FALC Mesothelial Cell Populations {#sec2.1}
------------------------------------------------------------------------------------------

To characterize the mesothelial and stromal cell populations of the omentum, we performed droplet-based scRNA-seq on isolated mouse omental CD45^−^CD41^−^Ter119^−^CD31^−^PDPN^+/−^ stromal cells from naive mice ([Figure 1](#fig1){ref-type="fig"}A). Unsupervised clustering identified five populations visualized using UMAP (uniform manifold approximation and projection) and a hierarchical cluster tree ([Figures 1](#fig1){ref-type="fig"}B and 1C). Cluster 1 was designated as mesothelial cells because differentially expressed genes (DEGs; genes with a 0.25 log-fold change and expressed in at least 25% of the cells in the cluster under comparison; [Table S3](#mmc2){ref-type="supplementary-material"}) were enriched for epithelial (*Upk1b*, *Upk3b*, *Krt19*, and *Krt7*) and mesothelial (*Msln* and *Cd200*) lineage marker genes ([Figures 1](#fig1){ref-type="fig"}D--1F and [S1](#mmc1){ref-type="supplementary-material"}A). Clusters 2 and 3 ([Figures 1](#fig1){ref-type="fig"}B and 1C) shared similarity with mesothelial cells in keeping with the expression of some epithelial lineage marker genes such as *Upk1b*, *Upk3b*, *Krt19*, and *Krt76* ([Figures 1](#fig1){ref-type="fig"}F and [S1](#mmc1){ref-type="supplementary-material"}A). Cluster 2 was distinguished by DEGs involved in the recruitment, adhesion, or activation of immune cells such as *Hdc*, *Enpp2*, *Ccl2*, *Cd44, Il34*, *Cxcl10*, *Cxcl13*, *Cd55*, *Ctsc*, *Ccl7*, and *Cxcl1* and was designated *Cxcl13*^*+*^ mesothelium ([Figures 1](#fig1){ref-type="fig"}D, 1E, 1G, and [S1](#mmc1){ref-type="supplementary-material"}B). A population of CXCL13^+^ stromal cells is found around the outside of FALCs ([@bib4], [@bib44]). The fact that *Cxcl13*^*+*^ mesothelial cells expressed mesothelial markers suggested that *Cxcl13*^*+*^ cells were covering the surface of FALCs. Cluster 3 was distinguished by DEGs associated with interferon signaling such as *Ifit3b*, *Ifit3*, *Ifit1*, and *Isg15*, and anti-viral responses such as *Rsad2*, and was designated as *Ifit*^*+*^ mesothelium ([Figures 1](#fig1){ref-type="fig"}D, 1E, 1H, and [S1](#mmc1){ref-type="supplementary-material"}C). Pathway analysis confirmed association of this cluster with interferon signaling and anti-viral mechanism terms ([Table S1](#mmc1){ref-type="supplementary-material"}). Pseudotime analysis of the mesothelial cell cluster (cluster 1) to the *Cxcl13*^*+*^ mesothelial cluster (cluster 2) showed the gradual up and downregulation of groups of genes along the mesothelial to *Cxcl13*^*+*^ mesothelial trajectory ([Figures S2](#mmc1){ref-type="supplementary-material"}A and S2C). Pseudotime analysis also revealed groups of genes whose expression were gradually up and downregulated along the mesothelial (cluster 1) to *Ifit*^*+*^ mesothelial (cluster 3) trajectory ([Figures S2](#mmc1){ref-type="supplementary-material"}B and S2D). This suggests that cells from the *Cxcl13*^*+*^ and *Ifit*^*+*^ mesothelial cell clusters derive from mesothelial cells and acquire specific immune functions.Figure 1Identification of Non-endothelial Stromal Cell Populations within the Omentum(A) CD45^−^CD41^−^Ter119^−^CD31^−^PDPN^+/−^ non-endothelial omental stromal cells were cell-sorted and underwent scRNA-seq.(B and C) Unsupervised clustering of non-endothelial omental stromal cells visualized with UMAP, where each dot is a single cell colored by cluster assignment (B) and hierarchical cluster tree (C).(D) Heatmap of each cell's (column) scaled expression of DEGs (row) expressed by a minimum of 30% of cells per cluster.(E) Gene expression distinguishing the five clusters projected onto UMAP plots. Color scaled for each gene with highest log-normalized expression level noted.(F--J) Violin plots of canonical omental stromal cell gene expression by cluster with highest log-normalized expression value labeled for the mesothelium (F and J), *Cxcl13*^+^ mesothelial cells (G), *Ifit*^+^ mesothelial cells (H), and *Ccl11*^*+*^*Pdgfra*^*+*^ and *Matn2*^*+*^*Pdgfra*^*+*^ fibroblasts (I).(K) Representative gating strategy of non-endothelial omental PDPN^+^PDFGRa^+^CD200^−^ (blue), PDPN^+^PDFGRa^int^CD200^int^ (green), and PDPN^+^PDFGRa^−^CD200^+^ (red) stromal cells and level of expression of CD44 and CD55 in these populations. Fluorescence minus one control (FMO) in gray.

scRNA-Seq Reveals the Presence of Two Distinct FALC Fibroblast Populations within Omental Stroma {#sec2.2}
------------------------------------------------------------------------------------------------

Clusters 4 and 5 displayed DEGs enriched for genes associated with fibroblasts such as *Fn1*, *Col4a1*, *Col14a1*, and *Pdgfra* ([Figures 1](#fig1){ref-type="fig"}D, 1I, and [S1](#mmc1){ref-type="supplementary-material"}D). Cluster 4 was distinguished by the expression of *Ccl11* (also called Eotaxin) and assigned the name *Ccl11*^*+*^*Pdgfra*^*+*^ fibroblasts ([Figures 1](#fig1){ref-type="fig"}B, 1E, and 1I). Cluster 5 was characterized by the expression of *Matn2.* FALC B cells of the omentum and mesenteries are embedded in a dense network of PDFGRα^+^ fibroblast reticular cells (FRCs) expressing *Ccl19* ([@bib41]). *Matn2*^*+*^*Pdgfra*^*+*^ fibroblasts expressed *Ccl19* and showed enrichment for genes involved in formation of the extracellular matrix (ECM) characteristic of lymph node (LN) and FALC FRCs such *as Sparcl, Spon2, Col15a1, Bgn, Emilin1*, and *Spon1* ([Figures 1](#fig1){ref-type="fig"}D, 1I, and [S1](#mmc1){ref-type="supplementary-material"}E) ([@bib18], [@bib30], [@bib41]). They represented a distinct subset of FRCs, whose gene expression profile did not fit into any of the LN stromal cell populations recently described by scRNA-seq ([@bib45]). In particular, *Matn2*^*+*^*Pdgfra*^*+*^ fibroblasts did not express *Il7*, *Ccl21*, *Bst1*, or *Cxcl9*, but expressed high levels of *Cd34* ([Figure 1](#fig1){ref-type="fig"}J), *Inmt*, and *Nr4a1* ([Figure S1](#mmc1){ref-type="supplementary-material"}E). The *Matn2*^*+*^*Pdgfra*^+^ fibroblast subset was distinct from the populations of fibroblasts identified in the inflamed synovium ([@bib11]) and did not expre*ss Fapa or Thy1*. *Ccl11*^*+*^*Pdgfra*^*+*^ fibroblasts did not express *Fapa* and showed only limited expression of *Thy1* ([Figure S1](#mmc1){ref-type="supplementary-material"}D), thus suggesting that the adipose tissue is associated with distinct and specific fibroblast subsets.

All five clusters expressed *Pdpn*, *Wt1*, *Cd34*, *Itgb1* (*Cd29*), and *Ly6a* (*Sca-1*), which have been used collectively to identify cells of mesothelial origin giving rise to adipocytes in visceral fat depots ([Figures 1](#fig1){ref-type="fig"}J and [S1](#mmc1){ref-type="supplementary-material"}F; [@bib10]). Regulation of retinol metabolism by *Wt1*-expressing cells is critical to maintain GATA6^+^ resident macrophages in the peritoneal cavity ([@bib8]). The two step-limiting enzymes of retinol metabolism were expressed by omental stromal cells with expression of *Aldh1a1* by mesothelial cells and *Aldh1a2* by both mesothelial cells and *Ccl11*^*+*^*Pdgfra*^*+*^ fibroblasts ([Figure S1](#mmc1){ref-type="supplementary-material"}F). *Il33* was expressed by all three mesothelial clusters ([Figure 1](#fig1){ref-type="fig"}J), in agreement with previous reports ([@bib29], [@bib47]) as well as in FALC FRCs, confirming our previous observation that IL-33 is expressed by FALC stromal cells ([@bib20]).

*Cxcl13*^*+*^ and *Ifit*^*+*^ Mesothelial Cells Are Present in Other Adipose Tissues Rich in FALCs {#sec2.3}
--------------------------------------------------------------------------------------------------

Distinct clusters of PDPN^+^PDGFRα^+^ fibroblasts and PDPN^+^PDGFRα^−^ mesothelial cells are found in the mesenteric adipose tissue ([@bib23]). As mesenteries contain FALCs, we reasoned that cells corresponding to *Cxcl13*^*+*^ and *Ifit*^*+*^ mesothelial cells should be identifiable within the mesenteric scRNA-seq dataset ([@bib23]). Projection of the mesenteric PDPN^+^PDGFRα^−^ mesothelial cell dataset onto our omental stromal dataset confirmed the presence of *Cxcl13*^*+*^ and *Ifit*^*+*^ mesothelial cells in the mesenteries ([Figures S2](#mmc1){ref-type="supplementary-material"}E--S2G). Projection of the mesenteric PDPN^+^PDGFRα^+^ fibroblasts onto our omental stromal dataset confirmed the presence of *Matn2*^+^ fibroblast cells in the mesenteries ([Figures S2](#mmc1){ref-type="supplementary-material"}E, S2F, and S2H).

We compared the gene expression profile of PDPN^+^PDGFRα^−^ mesothelium from the gonadal adipose tissue, which does not contain FALCs, with the PDPN^+^PDGFRα^−^ mesothelium of the omentum using published RNA-seq datasets ([@bib8]). A number of genes were overexpressed in the omental mesothelium, including DEGs characterizing the *Cxcl13*^*+*^ mesothelial cluster such as *Krt76*, *Cd55*, *Cd44*, *Ccl2*, *Hdc, Enpp2*, and *Cxcl1* ([Figure S1](#mmc1){ref-type="supplementary-material"}H; [Table S4](#mmc3){ref-type="supplementary-material"}). In our omental dataset, *Cxcl13*^*+*^ mesothelial cells were distinguished from mesothelial cells by 195 DEGs ([Table S5](#mmc4){ref-type="supplementary-material"}). Of these, 68 were also overexpressed in the omental mesothelium compared to the gonadal fat pad mesothelium of the Buechler et al. dataset ([Figure S1](#mmc1){ref-type="supplementary-material"}G), confirming that the *Cxcl13*^*+*^ mesothelial cluster was associated with the presence of FALCs in the adipose tissue.

Flow-cytometric analysis of FALC-rich tissues confirmed the presence of PDGFRα^−^PDPN^+^CD200^+^CD55^−/low^CD44^low^ mesothelial cells and PDGFRα^+^PDPN^+^CD200^−^CD55^int^CD44^−^ fibroblasts in the omentum and allowed the identification of a population of cells transitioning from PDGFRα^−^CD200^high^ to PDGFRα^+^CD200^−^ expressing high levels of CD55 and CD44 in keeping with the gene expression profile of *Cxcl13*^*+*^ mesothelial cells ([Figure 1](#fig1){ref-type="fig"}K). Detection of CD200 on the surface of *Cxcl13*^*+*^ mesothelium suggested maintenance of protein expression following *Cd200* transcript downregulation ([Figure 1](#fig1){ref-type="fig"}F) during differentiation from mesothelial cells. In mouse, the omentum is the tissue with the highest abundance of FALCs, followed by pericardium, mediastinum, and mesenteries ([@bib4]). In keeping with the relative abundance of FALCs in these tissues, the omentum was the tissue with the highest proportion of *Cxcl13*^*+*^ mesothelial cells identified as PDPN^+^PDGFRα^int^CD200^int^ cells, followed by the pericardium, mediastinum, and mesenteries. The gonadal adipose tissue, which does not contain FALCs, showed minimal PDPN^+^PDGFRα^int^CD200^int^ cells ([Figure S3](#mmc1){ref-type="supplementary-material"}A).

FALCs Are Covered by a Monolayer of Stromal Cells Expressing Markers of *Cxcl13*^*+*^ and *Ifit*^*+*^ Mesothelial Cells {#sec2.4}
-----------------------------------------------------------------------------------------------------------------------

To elucidate the spatial organization of FALCs, we performed wholemount immunofluorescence staining using marker genes identified from our scRNA-seq analysis. The B cell positioning chemokine CXCL13 was found within PDPN^+^ mesothelial cells covering the surface of omFALCs ([Figures 2](#fig2){ref-type="fig"}A and 2B; FALC), as well as pericardial FALCs ([Figure S3](#mmc1){ref-type="supplementary-material"}B). The morphology of these cells differed from the typical cobblestone appearance of PDPN^+^ mesothelial cells, which surrounded the FALC and did not express CXCL13 ([Figures 2](#fig2){ref-type="fig"}A and 2C; mesothelium). The lysophospholipase ENPP2 (Ectonucleotide Pyrophosphatase/Phosphodiesterase 2), expression of which was enriched in the *Cxcl13*^*+*^ FALC stromal cell population, was also present at high levels on the surface of FALCs and was expressed by CXCL13^+^ cells ([Figures 2](#fig2){ref-type="fig"}D, [S4](#mmc1){ref-type="supplementary-material"}A, and S4B). The lysosomal cysteine protease Cathepsin-C (*Ctsc*; also known as di-peptidyl peptidase I) was present within PDPN^+^ stromal cells covering omFALCs, but not within the mesothelial surface outwith the FALC ([Figures 2](#fig2){ref-type="fig"}E and [S4](#mmc1){ref-type="supplementary-material"}C). Our results thus confirm the existence of a mesothelial-derived population of cells covering the surface of FALCs and expressing ENPP2, CXCL13, and Cathepsin-C, which we named *Cxcl13*^*+*^ FALC cover cells. ISG15 was found in the cytoplasm of a subset of the PDPN^+^ cells covering omFALCs, confirming the existence of *Ifit*^*+*^ mesothelial cells. ENPP2 and ISG15 were co-expressed by PDPN^+^ cover cells ([Figures 2](#fig2){ref-type="fig"}F and [S4](#mmc1){ref-type="supplementary-material"}D). We named these cells *Ifit*^*+*^ FALC cover cells. PDPN^+^ FALC FRCs, which formed a reticular network at the core of the cluster, expressed very low levels of ENPP2 as predicted ([Figure S4](#mmc1){ref-type="supplementary-material"}A, enlargement 4). Finally, staining for CCL11 revealed that fibroblasts contained in the adipose (non-FALC) stroma of the omentum expressed high levels of CCL11, while FALC FRCs and mesothelial cells did not ([Figures S4](#mmc1){ref-type="supplementary-material"}E and S4F).Figure 2FALCs Are Covered by a Differentiated Monolayer of Mesothelial Cells(A) 3D reconstruction of a large portion of the omentum obtained by imaging of wholemount staining of the omentum showing omFALCs with DAPI (white).(B and C) Confocal imaging and 3D reconstruction of an omFALC showing a view of the surface of the cluster and a z section (along the dotted line) of the cluster (B) and of the surface of the omentum (C) with PDPN (red), CXCL13 (green), DAPI (blue), and IgM (yellow).(D--F) Representative confocal imaging and 3D reconstruction of an omFALC showing a view of the surface of the cluster and a z section (dotted line) of the cluster with PDPN (red); ENPP2 (D, green), Cathepsin-C (E, CTSC, green), or ISG15 (F, green); DAPI (blue) and IgM (D, yellow); or CD45 (E and F, yellow). The surface of the cluster and the mesothelium are delimited by a hyphenated line.(G) Violin plots of gene expression of inflammatory chemokines by cluster with highest log-normalized expression value labeled.(H) Amounts of CCL2, CXCL10, and CXCL1 secreted into the supernatant of 2-h omentum explant culture per omentum and per ml after exposure to Zymosan-A for 2 h either *in vivo* (i.p. injection) or *ex vivo*. Data pooled from two independent experiments with n = 10 mice per group.(I) Confocal imaging and 3D reconstruction of omFALC showing the surface of omFALCs (first column) and a clipped view inside the cluster (second column). Scale bars, 100 μm.All staining representative of n ≥ 8 clusters from n ≥ 4 mice in at least two independent experiments. Error bars show SEM. Kruskal Wallis test with Dunn's multiple comparisons test or ANOVA with Sidak's multiple comparisons test was applied after assessing normality using D'Agostino and Pearson normality test, ns = non-significant, ^∗∗∗^p = \< 0.001.

*Cxcl13*^*+*^ FALC Cover Cells Express Inflammatory Chemokines {#sec2.5}
--------------------------------------------------------------

The *Cxcl13*^*+*^ FALC cover cell cluster was distinguished by the expression of the monocyte chemoattractants *Ccl2* and *Ccl7* and the neutrophil chemoattractants *Cxcl1* and *Cxcl10* ([Figure 2](#fig2){ref-type="fig"}G), suggesting a role for these cells in orchestrating the recruitment of inflammatory cells during peritonitis. The expression of *Cxcl1* was also enriched in *Ccl11*^*+*^*Pdgfra*^*+*^ fibroblasts and *Matn2*^*+*^*Pdgfra*^*+*^ fibroblasts. Analysis of omental explant culture supernatants showed that CXCL1 protein was released at steady state by the omentum and that CXCL1 secretion was potentiated after a 2 h exposure to Zymosan-A, *in vivo* or ex *vivo* ([Figure 2](#fig2){ref-type="fig"}H). In contrast, the two other early chemo-attractants, CCL2 and CXCL10, were released by the omentum only after peritoneal inflammation was triggered by Zymosan-A, and this could not be recapitulated *ex vivo* ([Figure 2](#fig2){ref-type="fig"}H). This suggests that CXCL1 is constitutively produced by the omentum, while the initial secretion of CCL2 and CXCL10 is dependent on the early recruitment of immune cells upon sensing of an inflammatory signal. In addition, the rapid induction of secretion of CXCL1 (2 h) suggests that this is due to release of pre-formed CXCL1 rather than an increase in transcription. Radiation-resistant stromal-derived CXCL1 is important in the control of bacterial infection during peritonitis ([@bib21]). Protein expression of CXCL1 was particularly high in FALC cover cells within the omentum ([Figure 2](#fig2){ref-type="fig"}I), as well as the pericardium and mesenteries ([Figures S3](#mmc1){ref-type="supplementary-material"}C and S3D). While the expression of *Cxcl1* was comparable in the *Cxcl13*^*+*^ mesothelial cell cluster and the *Matn2*^*+*^*Pdgfra*^*+*^ and *Ccl11*^*+*^*Pdgfra*^*+*^ fibroblast clusters, CXCL1 protein was much higher in FALC cover cells, suggesting that these cells retain intracellular stores of CXCL1. Given the spatially constrained expression of CXCL1 over the surface of FALCs and that neutrophils use FALC HEVs to enter the peritoneal cavity ([@bib9]), we next assessed whether CXCL1 was important for the recruitment of neutrophils to omFALCs during peritonitis.

CXCL1 Mediates Active Recruitment of Neutrophils into omFALCs {#sec2.6}
-------------------------------------------------------------

To characterize the dynamics of neutrophil recruitment to omFALCs during peritonitis, we used the well-established murine model, Zymosan-A-induced peritonitis. Peritonitis led to a transient increase in the number of Ly6G^+^ neutrophils in the omentum, peaking at 24 h ([Figures 3](#fig3){ref-type="fig"}A and [S5](#mmc1){ref-type="supplementary-material"}A). Wholemount immunofluorescence staining and confocal analysis revealed that FALCs were the site of extensive recruitment of Ly6G^+^ Myeloperoxidase^+^ (MPO) neutrophils, which formed dense cellular aggregates between 6 and 24 h post-induction of peritonitis ([Figures 3](#fig3){ref-type="fig"}B, 3C, and [S5](#mmc1){ref-type="supplementary-material"}B). The volume of omFALCs increased exponentially during the first 18 h post-Zymosan injection (75-fold) before rapidly contracting back to their normal size by 24 h ([Figure 3](#fig3){ref-type="fig"}D). This timing coincided with the influx of MPO^+^ neutrophils and their disappearance by 24 h ([Figures 3](#fig3){ref-type="fig"}C and 3D). This accretion of neutrophils was specific to omFALCs and did not happen on the rest of the surface of the omentum, the diaphragm, or the parietal wall ([Figures 3](#fig3){ref-type="fig"}E, [S5](#mmc1){ref-type="supplementary-material"}C, and S5D). We then tested whether CXCL1 was involved in the accumulation of neutrophils at omFALCs during peritonitis, using an anti-CXCL1 blocking antibody. Eighteen hours post-Zymosan injection, CXCL1 blockade led to a 2.6-fold decrease in the number of neutrophils recovered from the omentum compared to mice treated with isotype control antibodies. There was no difference in the number of neutrophils recovered from the peritoneal cavity, suggesting that the trafficking of neutrophils through omFALC HEVs was not altered ([Figure 3](#fig3){ref-type="fig"}F). Thus, the extensive recruitment of neutrophils to FALCs is not simply a consequence of increased trafficking of neutrophils through HEVs, but the result of active retention dependent upon CXCL1.Figure 3CXCL1 Is Required for the Recruitment of Neutrophils into omFALCs(A) Number of neutrophils in digested omentum as assessed by flow-cytometric analysis ([Figure S5](#mmc1){ref-type="supplementary-material"}A) of naive (white bar) and at the indicated time points following i.p. injection of Zymosan-A (blue bars). Data pooled from two independent experiments with n = 5--11 mice per group.(B) Representative confocal imaging and 3D reconstruction of omFALCs from naive and 6 h post-Zymosan mice, DAPI (magenta) and Ly6G (white). Scale bar, 200 μm.(C) Quantification of the mean gray value of Ly6G and MPO stained as in [Figure S5](#mmc1){ref-type="supplementary-material"}B of omenta from naive (white bar) and at the indicated time points following i.p. injection of Zymosan (blue bars). Data for cluster quantification pooled from two independent experiments with n ≥ 24 imaged clusters from n = 8 mice per group.(D) Quantification of the volume of omFALCs at the indicated times following i.p. injection of Zymosan-A (blue). Data pooled from two independent experiments with n ≥ 32 imaged clusters from n = 6 mice per group.(E) Representative confocal images of omentum, the peritoneal surface of the diaphragm, and parietal wall from naive and 6 h post-Zymosan mice, DAPI (magenta) and Ly6G (white) and quantification of the mean gray value of Ly6G for omFALCs, parietal wall, diaphragm from naive (white) and 6 h post-Zymosan mice (blue). Data for cluster quantification pooled from two independent experiments with n ≥ 24 imaged clusters from n = 6 mice per group. Scale bar, 50 μm.(F) Representative density plots showing proportion of neutrophils found in the peritoneal exudate cells (PECs) and omentum 18 h post Zymosan i.p injection, in combination with the injection of anti-CXCL1 or isotype control antibodies after 2 h and number of neutrophils found in PECs and per g of omentum in naive and treated mice. Data pooled from two independent experiments with n = 5--11 mice per group.Error bars show SEM. Box and whiskers showing min to max value. Kruskal Wallis test with Dunn's multiple comparisons test or ANOVA with Sidak's multiple comparisons test was applied after assessing normality using D'Agostino and Pearson normality tests, ns = non-significant, ^∗^ = p \< 0.05, ^∗∗^ = p \< 0.01, ^∗∗∗^p = \< 0.001, ^∗∗∗∗^p = \< 0.0001.

To confirm that the omentum is a major source of CXCL1 during peritonitis, we quantified secretion of CXCL1 following 2 h *ex vivo* explant culture of omentum, mesenteries, peritoneal wall, diaphragm, and liver from naive mice and at 2 h following injection of Zymosan-A. In contrast to liver, the mesenteries, peritoneal wall, and diaphragm all significantly increased secretion of CXCL1 following exposure to Zymosan-A *in vivo*; however, per mg of tissue, the omentum secreted significantly more CXCL1 than any of these peritoneal tissues ([Figure S5](#mmc1){ref-type="supplementary-material"}E). Having established that FALC cover cells constituted an important store of CXCL1, and that inflammation led to rapid release of pre-formed CXCL1, we next assessed the effect of inflammation on the expression of *Cxcl1* mRNA in various omental cell fractions: PDPN^+^CD31^−^PDGFRα^+^CD200^−^ fibroblasts, PDPN^+^CD31^−^PDGFRα^int^CD200^int^ FALC cover cells, PDPN^+^CD31^−^PDGFRα^−^CD200^+^ mesothelial cells, PDPN^−^CD45^−^CD31^+^ endothelial cells, and CD45^+^ hematopoietic cells. Two hour Zymosan-A exposure significantly increased the transcription of *Cxcl1* by all populations assessed, except the hematopoietic population, where *Cxcl1* expression remained low, confirming the stromal origin of CXCL1 within the omentum. The highest expression of *Cxcl1* was found in fibroblasts and FALC cover cells ([Figure S5](#mmc1){ref-type="supplementary-material"}F).

Neutrophils Form Large Aggregates in omFALCs, Which Are Encapsulated in NET-like Structures {#sec2.7}
-------------------------------------------------------------------------------------------

Immunofluorescence imaging analysis of accumulated neutrophils within omFALCs revealed the presence of multiple areas of DAPI staining presenting with a non-nuclear appearance ([Figure 4](#fig4){ref-type="fig"}A, right). Neutrophils have the capacity to form NETs, which consist of uncoiled DNA scaffold decorated with proteases and anti-microbial peptides found in neutrophil granules. NETs are formed as a defense mechanism to immobilize invading microorganisms but also in response to sterile triggers ([@bib7], [@bib38]). In some conditions, NETs mediate neutrophil aggregation ([@bib26], [@bib37], [@bib46]). Chromatin decondensation, which is required for the formation of NETs, can be mediated by the citrullination of histones. Staining for citrullinated histone H3 (CitH3) revealed that the areas of DAPI staining presenting with an extruded DNA pattern were highly stained for CitH3 ([Figure 4](#fig4){ref-type="fig"}A). CitH3^+^ DNA was found in FALCs between 6 and 18 h post-Zymosan injection at the peak of neutrophil recruitment ([Figures 4](#fig4){ref-type="fig"}B, [3](#fig3){ref-type="fig"}A, and 3C). The highest density of CitH3^+^ DNA was found on the surface of the expanded FALCs, which typically formed a dense core of neutrophils coated with a CitH3^+^ DNA outer-layer ([Figures 4](#fig4){ref-type="fig"}C, [S6](#mmc1){ref-type="supplementary-material"}A, and S6B).Figure 4CitH3^+^ DNA Coats Neutrophil Aggregates on omFALCs during Peritonitis(A) Representative confocal images of wholemount staining of omentum from naive and 6 h post-Zymosan mice DAPI (magenta), CitH3 (green), and Ly6G (blue). Scale bar, 50 μm.(B) Quantification of the number of CitH3 positive nuclei per mm at the times indicated post-Zymosan injection. Data for cluster quantification pooled from two independent experiments with n ≥ 24 imaged clusters from n = 8 mice per group. Box and whiskers showing min to max value.(C) 3D reconstruction of omFALC at 6 h post-Zymosan injection showing the surface of a cluster (first row) and a clipped view inside the cluster (second row). Ly6G (blue), CitH3 (green), DAPI (magenta). Scale bar, 100 μm.(D) WT or *Elane*^−/−^ mice were left naive (WT white, *Elane*^−/−^ gray) or injected i.p. with Zymosan (WT blue, Elane^−/−^ gray). Omenta were collected 18 h post-injection. The number of CitH3^+^ cells per mm and volume of each cluster were assessed by wholemount staining and confocal analysis of omenta from naive and treated mice. Data for cluster quantification pooled from two independent experiments with n ≥ 14 (CitH3^+^ cells) or n ≥ 20 (cluster size) imaged clusters from n = 4 mice per group.(E) Representative confocal images of omFALCs at 6 h following Zymosan injection showing MPO (green), Ly6G (blue), CitH3 (white), and DAPI (magenta). Staining representative of n ≥ 24 clusters from n ≥ 8 mice in two independent experiments. Scale Bar, 50 μm.Student's t test, Kruskal Wallis test with Dunn's multiple comparisons test, or Mann Whitney test was applied after assessing normality using D'Agostino and Pearson normality test, ns = non-significant, ^∗∗∗∗^p = \< 0.0001.

To further characterize the CitH3^+^ DNA outer-layer and determine if it could be considered as NETs, we analyzed the requirement for Neutrophil elastase (NE). NE is a granule serine protease which translocates to the nucleus, where it promotes chromatin decondensation and the formation of NETs ([@bib39]). Here, we found that the formation of the CitH3^+^ DNA layer coating omFALC neutrophil aggregates, and the expansion of these structures during Zymosan-induced peritonitis was not affected in NE-deficient *Elane*^−/−^ mice compared to wild-type (WT) mice ([Figure 4](#fig4){ref-type="fig"}D). MPO, another granule serine protease, synergizes the action of NE and is found associated with NETs ([@bib39]). Staining for MPO revealed that the CitH3^+^ DNA covering the neutrophil aggregates was not associated with MPO, suggesting that MPO relocation to the nucleus is not required for the formation of the CitH3^+^ DNA outer-layer ([Figure 4](#fig4){ref-type="fig"}E). Given that the neutrophil aggregates formed independently of NE, we sought to confirm that the aggregates were formed by neutrophils. Injection of anti-Gr1 antibodies successfully mediated depletion of the Ly6G^+^ peritoneal neutrophil population at 6 h following Zymosan-A intraperitoneal (i.p.) injection ([Figure S7](#mmc1){ref-type="supplementary-material"}A). Following depletion of peritoneal neutrophils, no accretion of Ly6G^+^ neutrophils, staining for CitH3^+^, nor expansion in cluster volume occurred within the omentum ([Figure S7](#mmc1){ref-type="supplementary-material"}B). Therefore, the formation of the CitH3^+^ DNA layer coating the omFALC aggregates that appear during Zymosan-induced peritonitis is formed by neutrophils independently of NE and thus different from the formation of "classical" NETs.

Inhibition of PAD4 Prevents the Aggregation of Neutrophils in omFALCs and the Trapping of Zymosan by omFALCs {#sec2.8}
------------------------------------------------------------------------------------------------------------

The enzyme PAD4, which mediates the conversion of arginine into citrulline, is implicated *in vitro* and *in vivo* in the formation of NETs. The role of PAD4 in NET formation remains controversial and seems to be context dependent ([@bib7], [@bib24]). In order to test whether PAD4 was involved in the capture of particulate contaminants and the formation of neutrophil aggregates on omFALCs, we used fluorescently labeled Zymosan (Fluo-Zym) and the specific PAD4 inhibitor GSK484 ([@bib27]). Observation of the omentum with a stereo-microscope at 6 h post-injection revealed that omFALCs had undergone a massive expansion and very effectively captured and concentrated Fluo-Zym particles in FALCs ([Figure 5](#fig5){ref-type="fig"}A). In contrast to the omentum, the epidydimal fat pad, parietal wall, and diaphragm did not capture any Fluo-Zym ([Figure S7](#mmc1){ref-type="supplementary-material"}C). The Fluo-Zym particles were concentrated in dispersed spots on the mesenteries in keeping with the lower proportion of FALCs within this tissue compared to the omentum. PAD4 inhibition completely abrogated both the omFALC expansion and the capture of Fluo-Zym particles by omFALCs ([Figures 5](#fig5){ref-type="fig"}A--5C). Fluo-Zym injection led to the formation of large neutrophil aggregates embedded in CitH3^+^ DNA, while PAD4 inhibition blocked the recruitment of Ly6G^+^ neutrophils into omFALCs and significantly reduced the CitH3 staining compared to Fluo-Zym-only controls ([Figures 5](#fig5){ref-type="fig"}B and 5D). PAD4 inhibition was associated with omFALCs failing to capture Fluo-Zym particles and expand in size ([Figures 5](#fig5){ref-type="fig"}A and 5E).Figure 5Inhibition of PAD4 Prevents Neutrophil Aggregation and Capture of Zymosan Particles within omFALCs While Increasing the Retention of Zymosan in the Peritoneal Cavity and Spread to the SpleenMice were left naive (white) or injected i.p. with Fluo-Zym in combination with the PAD4 inhibitor GSK484 (red) or vehicle (blue) and the omentum. PECs and spleen were analyzed 6 h post injection.(A and B) Representative low (A**,** scale bar 1 mm) and high (B, scale bar 50 μm) magnification confocal images of wholemount immunofluorescence staining of omentum.(C--E) Number of Fluo-Zym particles per mm^2^ of omFALCs (C), mean gray value for CitH3 and Ly6G staining (D), volume of omFALCs (E).(F) Total number of PEC neutrophils.(G) Representative histogram showing fluorescence intensity of Fluo-Zym in all PECs and number of Fluo-Zym^+^ PECs.(H) Number of Fluo-Zym^+^ neutrophils and MFI of Fluo-Zym within Fluo-Zym^+^ neutrophils.(I) Representative histogram showing fluorescence intensity of Fluo-Zym in spleen and percentage and number of Fluo-Zym^+^ events per spleen.Data for cluster quantification pooled from two independent experiments with n ≥ 30 (C--D) and n ≥ 60 (E) imaged clusters from n = 7--8 mice per group. Data pooled from two independent experiments with n = 7--8 mice per group. Kruskal Wallis test with Dunn's multiple comparisons test or Mann Whitney test was applied after assessing normality using D'Agostino and Pearson normality test, ns = non-significant, ^∗∗^ = p \< 0.01, ^∗∗∗^p = \< 0.001, ^∗∗∗∗^p = \< 0.0001.

In contrast, GSK484 did not block the recruitment of neutrophils into the peritoneal cavity since we recovered twice as many neutrophils from the peritoneal cavity when mice received GSK484 and Fluo-Zym compared to Fluo-Zym only ([Figure 5](#fig5){ref-type="fig"}F). Thus, GSK484 inhibits neutrophil accretion in omFALCs, leading to a very severe reduction in the capacity of the omentum to capture Zymosan particles. While neutrophils clearly underwent citrullination of Histone H3 during Zymosan-induced peritonitis, the fact that PAD4 inhibition led to a near-complete abrogation of neutrophil aggregation within FALCs did not allow us to conclude whether PAD4 was involved in the formation of the CitH3^+^ DNA outer-layer we observed.

Inhibition of PAD4 Leads to Impaired Clearance of Zymosan Particles from the Peritoneal Cavity and Increases Dissemination to the Spleen {#sec2.9}
----------------------------------------------------------------------------------------------------------------------------------------

We next addressed the effect of PAD4 inhibition on peritoneal neutrophil clearance of Zymosan-A. Inhibition of PAD4 resulted in a significant increase in the retention of neutrophils and Fluo-Zym particles within the peritoneal cavity ([Figures 5](#fig5){ref-type="fig"}F and 5G). There was a 3-fold increase in the proportion of neutrophils retaining Fluo-Zym particles, with a near 2-fold increase in Fluo-Zym mean fluorescence intensity (MFI), indicating that PAD4 inhibition led to increased phagocytosis of Fluo-Zym particles by peritoneal neutrophils ([Figure 5](#fig5){ref-type="fig"}H). Finally, PAD4 inhibition led to increased dissemination of Fluo-Zym particles to the spleen ([Figure 5](#fig5){ref-type="fig"}I). Thus, this suggests that PAD4-dependent neutrophil aggregation within omFALCs provides a rapid and efficient mechanism to clear particulate material from the peritoneal cavity and limit the systemic spread of peritoneal contaminants.

Neutrophil Recruitment and Aggregation Confer Increased Adhesive Properties to omFALCs {#sec2.10}
--------------------------------------------------------------------------------------

In the peritoneal cavity, the capture of particles by omFALCs results from a combination of peritoneal fluid flow through the omentum and the capacity of the omentum to retain these particles. To assess the importance of neutrophil aggregation on the adhesive properties of the omentum independent of fluid flow, we measured *ex vivo* the capacity of the omentum to capture bacteria relevant to peritonitis by briefly incubating fluorescently labeled *E. coli* bioparticles with omentum samples isolated from untreated control mice, or from mice undergoing Zymosan-induced peritonitis that had been treated with isotype control antibodies or anti-CXCL1 antibodies *in vivo* ([Figure 6](#fig6){ref-type="fig"}A). Omenta were collected at 18 h post-Zymosan injection and incubated *ex vivo* for 5 min at room temperature with *E. coli* bioparticles before fixation and wholemount immunofluorescence imaging. Omentum tissue sampled from mice with peritonitis proficiently trapped *E. coli*, whereas those from control mice without peritonitis did not ([Figure 6](#fig6){ref-type="fig"}A). Blockade of CXCL1 resulted in fewer neutrophils within the omentum and a failure to efficiently trap *E. coli,* indicating that CXCL1-mediated recruitment of neutrophils to the omentum dramatically increased the capacity of the omentum to capture bacterial contaminants. We confirmed the importance of neutrophil recruitment and aggregation for the increased adhesive properties of the omentum during peritonitis using omenta isolated from naive mice, those undergoing peritonitis, those undergoing peritonitis with PAD4 inhibition, and *E. coli* expressing the fluorescent protein mCherry. Omenta from naive mice did not trap *E. coli*, contrary to omenta from mice with peritonitis (containing NET-like structures), where large areas of FALCs were covered in *E. coli.* PAD4 inhibition led to a marked decrease in the efficiency with which the omentum captured *E. coli* ([Figure 6](#fig6){ref-type="fig"}B). These data suggest that neutrophil aggregation within omFALCs during peritonitis contributes to omental clearance of peritoneal bacterial contaminants.Figure 6CXCL1 and PAD4 Are Required for the Adhesion of Bacteria to the Omentum in the Absence of Fluid Flow(A) Representative confocal images of wholemount staining of omenta, isolated from either naive animals or 18 h after Zymosan i.p injection, in combination with the injection of either anti-CXCL1 or isotype control antibodies, and cultured with fluorescently labeled *E. coli* bio-particles for 10 min. Number of *E. coli* bioparticles found per cluster section and per μm^2^ of cluster were graphed. MPO (white), *E. coli* (green), DAPI (red), Ly6G (blue). Data for cluster quantification pooled from two independent experiments with n ≥ 18 imaged clusters from n = 10--11 mice per group. Error bars show SEM.(B) Mice were left naive (white circles) or injected i.p. with Zymosan in combination with the PAD4 inhibitor GSK484 (gray circles) or vehicle (blue circles). The omenta were collected 18 h post-injection and incubated *in vitro* for 5 min with mCherry^+^*E. coli*. Representative confocal images of wholemount staining of omentum. *E. coli* (green), DAPI (magenta). Mean gray value of *E. coli* in omFALCs and percentage area covered by *E. coli.*Data for cluster quantification pooled from two independent experiments with n ≥ 10 imaged clusters from n = 7--8 mice per group. Error bars show SEM. Kruskal Wallis test with Dunn's multiple comparisons test were applied after assessing normality using D'Agostino and Pearson normality tests, ns = non-significant, ^∗∗^ = p \< 0.01, ^∗∗∗^p = \< 0.001, ^∗∗∗∗^p = \< 0.0001. Scale bars, 50 μm.

Neutrophils Are Recruited to the Human Omentum during Peritonitis {#sec2.11}
-----------------------------------------------------------------

We reasoned that appendicitis would provide a useful translational platform to examine the function of the omentum during peritonitis. During acute appendicitis, the omentum wraps itself around and adheres to the inflamed appendix ([@bib35]). By comparison, in patients undergoing laparoscopic surgery for biliary colic (surgery for gallstones without active inflammation), the omentum and appendix are both uninvolved. We recruited patients who were undergoing laparoscopic surgery for possible or suspected acute appendicitis or laparoscopic cholecystectomy for biliary colic (non-inflamed, NI; [Table S2](#mmc1){ref-type="supplementary-material"}). Acute appendicitis induced a stark influx of CD16^+^CD14^−^CD19^−^CD3^−^CD56^−^CD15^+^ neutrophils into the omentum and the peritoneal cavity ([Figures 7](#fig7){ref-type="fig"}A and 7B).Figure 7The Human Omentum Recruits Neutrophils and Collects Bacterial Antigens during Appendicitis(A,) Representative gating strategy showing CD45^+^ CD19^−^, CD3^−^, NCAM^−^, and CD15^+^ neutrophils in the omentum (Om) of non-inflamed (NI) and appendicitis (App) patients. Histogram showing expression of CD16 and CD14 by omental neutrophils from representative patients with App, and quantification of CD16 and CD14 MFI on CD15^+^ neutrophils from NI (white) and appendicitis (red) patients.(B) Number of neutrophils found per g of Om or per ml of peritoneal wash (PW) of NI and App patients. Patients were stratified based on surgical outcome into one of two groups, NI (white) or App (red), n = 7 and 10 patients per group. Error bars show SEM.(C,) Chemokines and cytokines found in 2 h Om explant culture supernatant, PW, and serum comparing NI and App patients. Each column represents one patient.(D) Amounts of CXCL8 per g per ml of 2 h Om explant culture supernatant.(E) Representative confocal images of wholemount immunofluorescence staining of omentum biopsies from NI or App patients (n ≥ 6) showing in gray DNA stained with DAPI (upper) or extracellular DNA stained with SYTOX (middle, gray), or CD15 (lower); in magenta CD11b; in green MPO and in red Citrullinated histone H3 (CitH3).(F) Amounts of double-stranded DNA (dsDNA) released into the supernatant of 2 h omental explant culture per g and per ml and per ml of PW in control and App patients.(G) LAL activity within the supernatant of 2 h omental explant culture per g and per ml of PW and serum in control and appendicitis patients. n = 10--13 patients per group.Error bars show SEM. Unpaired Student's t test or Mann Whitney test was applied after assessing normality using D'Agostino and Pearson and Shapiro-Wilk normality tests, ns = non-significant, ^∗^ = p \< 0.05, ^∗∗^ = p \< 0.01, ^∗∗∗^p = \< 0.001.

We next investigated whether the mechanisms regulating recruitment of neutrophils to the human omentum were similar to mouse by analyzing the secretion of inflammatory chemokines and cytokines over a 2 h interval in *ex vivo* human omentum explant cultures ([Figure 7](#fig7){ref-type="fig"}C). CXCL8 (human homolog of murine CXCL1) and IL-1β, two important factors for neutrophil recruitment and activation ([@bib5]), were secreted at much higher levels in omental explant cultures and peritoneal lavage in inflammatory conditions compared to controls, but not in serum ([Figures 7](#fig7){ref-type="fig"}C and 7D). In patients with acute appendicitis, 1 g of omental explant released 25 ng of CXCL8, approximately 400 times more than the amount found per ml of peritoneal lavage, despite the number of neutrophils being similar in equivalent volumes of omentum and wash fluid ([Figures 7](#fig7){ref-type="fig"}B and 7D), indicating that the human omentum is a key site of CXCL8 release and neutrophil recruitment during peritonitis.

CitH3^+^ NET-like Structures Are Released on the Human Omentum during Peritonitis {#sec2.12}
---------------------------------------------------------------------------------

Finally, we tested whether neutrophils recruited to the omentum during peritonitis in humans also released CitH3^+^ NET-like structures. Wholemount immunofluorescence staining showed the presence of extracellular DNA fibrils stained with SYTOX or DAPI, which co-localize with CitH3, in regions where there was a substantial CD15^+^ neutrophil infiltrate during acute appendicitis ([Figure 7](#fig7){ref-type="fig"}E). Areas of CitH3^+^ DNA staining which did not co-localize with MPO were found, comparable to the murine omentum during peritonitis. No NET-like structures were detected in any NI control samples ([Figure 7](#fig7){ref-type="fig"}E). Double-stranded (ds)DNA was found in omental explant culture supernatants and in the peritoneal wash fluid from patients with acute appendicitis, but not from control patients ([Figure 7](#fig7){ref-type="fig"}F). Since an equivalent number of neutrophils were present per g of omentum and per ml of peritoneal wash ([Figure 7](#fig7){ref-type="fig"}B), the fact that dsDNA was released in the greatest amounts by the omental explants strongly suggests that the omentum supports DNA release from neutrophils. Using a limulus amoebocyte lysate (LAL) assay, we measured bacterial LPS within omental explant cultures and detected LPS release into culture supernatants from omentum isolated from patients with acute appendicitis, but not from NI patients. Patients with appendicitis also had higher serum levels of LPS, but there was no evidence of LPS within the peritoneal wash ([Figure 7](#fig7){ref-type="fig"}G). This suggested that during appendicitis, neutrophil aggregation and the release of CitH3^+^ NET-like structures on the omentum mediate successful capture of bacterial antigens arising from the inflamed appendix and thus protect the wider peritoneal cavity from contamination and generalized peritonitis.

Discussion {#sec3}
==========

In the present study, we uncovered important facets of stromal-immune cell interactions, which governed omFALC function within the peritoneal cavity and revealed how neutrophils mediated the clearance of peritoneal contaminants by omFALCs. The surface of FALCs was covered by differentiated mesothelial cells specialized in the secretion of inflammatory mediators (*Cxcl13*^*+*^ FALC cover cells) and the response to virus (*Ifit*^*+*^ FALC cover cells). During peritonitis, neutrophils rapidly accumulated within omFALCs, where they formed large aggregates concentrating peritoneal contaminants. The formation of these aggregates was dependent on two mechanisms: (1) CXCL1, which was produced by Cxcl13^+^ FALC cover cells; and (2) the PAD4-dependent formation of a CitH3^+^ DNA outer-layer coating the omFALC neutrophil aggregates. In humans with appendicitis, the omentum was also a site of neutrophil recruitment and the release of CitH3^+^ DNA. In addition, we provided evidence that the omentum efficiently captured bacterial antigens, leaving the peritoneal cavity free of contamination.

In the omentum, the mesothelium acts as a filtration system for peritoneal fluid. Entrance of peritoneal fluid is facilitated by the presence of stomata ([@bib34]) that afford particles and cells entrance into FALCs and enable fluid to be drained into neighboring lymphatic vessels. Our analysis revealed the exquisite adaptation of the mesothelium for this function, which gave rise to *Cxcl13*^*+*^ FALC cover cells, specialized in the attraction of immune cells and the secretion of inflammatory mediators and *Ifit*^*+*^ FALC cover cells competent for the secretion of anti-viral factors. Cxcl1 was expressed by both *Cxcl13*^*+*^ FALC stromal cells and *Pdgfra*^*+*^ fibroblast, but only FALC cover cells had intra-cellular stores of CXCL1, suggesting that CXCL1 production was post-transcriptionally regulated in FALC cover cells. In absence of a genetic model allowing the specific deletion of *Cxcl1* in FALC cover cells, we cannot rule out that CXCL1 from other cellular sources is important for the recruitment of neutrophils to the omentum. Based on our results, we hypothesize that following the initial *Cxcl13*^*+*^ FALC cover cell CXCL1 mediated recruitment of zymosan-loaded peritoneal neutrophils to omFALCs; the release of extracellular DNA facilitates the adhesion of further waves of neutrophils, which also extrude their DNA, resulting in the large aggregates imaged at 6--18 h. To account for the staining pattern seen, we assume that re-modeling of the DNA extrusions must occur to clear CitH3 from the center of the aggregates while leaving the fluid-facing aggregates coated in NET-like structures. This intriguing CitH3^+^ DNA outer-coating raises multiple questions., (1) what is the role of the CitH3^+^ DNA on the fluid facing surface of the cluster; are CitH3^+^ neutrophil-aggregated omFALCs anti-bacterial? (2) Are the aggregations performing a purely structural role by barricading the omFALC to limit the spread of peritoneal contaminants? (3) How are the aggregates cleared during the resolution of peritonitis? (4) Does resolution require exposure of CitH3^+^ DNA?

In sepsis, NETs promote a toxic inflammatory and procoagulant host response to endotoxin ([@bib31]). However, our data point toward an important role for omental NET release to limit the propagation of contaminants from the peritoneal cavity to the circulation. Due to constant drainage of peritoneal fluid through FALCs and their high vascularization ([@bib9], [@bib13], [@bib16]), FALCs are the main portals for the systemic transit of peritoneal contaminants. Additional experiments are required to further investigate the effect of PAD4 inhibition on neutrophil trafficking to secondary lymphoid organs during peritonitis; altered neutrophil trafficking may influence the export of peritoneal contaminants through the draining LNs and spleen. While targeted NET release on omFALCs is beneficial during peritonitis, it may play a detrimental role in ovarian cancer metastasis ([@bib25]).

Resident peritoneal macrophages undergo a clotting response within the first 2 h of contamination of the peritoneal cavity, providing a means of clearing peritoneal contaminants via coagulation and adhesion ([@bib50]). This mechanism serves to convert fluid phase inflammation to a solid state within the clots. Neutrophil aggregation within FALCs also enables the conversion to a solid state, which is required for efficient clearing of particles from the fluid phase. In doing so, neutrophils provide a timely relay for the neutralization of peritoneal contaminants, since resident peritoneal macrophages are rapidly sequestered in clots ([@bib50]). In gout and pancreatitis, presence of high-density neutrophils in combination with the release of NETs leads to the formation of large DNA aggregates. In gout, these aggregated NETs have the ability to degrade cytokines and chemokines via serine proteases and may be important to limit inflammation ([@bib46]). In pancreatitis, PAD4 mediates the release of NETs, which cause neutrophil aggregation and occlusion of pancreatic ducts ([@bib26]). Aggregated NETs have been implicated in the formation of gallstones ([@bib37]); Muñoz et al. report that uptake of small crystals results in NET release that is dependent upon PAD4. Here, we show that omFALCs are also sites where high densities of actively phagocytosing neutrophils aggregate in a PAD4-dependent mechanism during peritonitis.

Previous studies have posited that both MPO and NE are necessary for the release of bona fide NETs ([@bib32], [@bib39]). Here, we found that the release of CitH3^+^ DNA and aggregation of neutrophils over the surface of expanded omFALCs during peritonitis occurred even in the absence of NE, suggesting a mechanism of DNA release that did not conform to the same rules as classical NET formation. In addition, CitH3^+^ DNA did not robustly co-localize with MPO staining, again indicating a non-classical mechanism of neutrophil CitH3^+^ DNA release. In contrast to NE, the formation of omFALC neutrophil aggregates was dependent upon PAD4. Taken together, our findings contribute to mounting evidence that mechanisms of NET release vary, dependent upon context and location ([@bib7]).

STAR★Methods {#sec4}
============

Key Resources Table {#sec4.1}
-------------------

REAGENT or RESOURCESOURCEIDENTIFIER**Antibodies**Rat IgG2a anti-mouse CXCL1 antibody, clone 48415InvitrogenCat\# MA5-23745\
RRID:[AB_2609463](nif-antibody:AB_2609463){#intref0010}Rat IgG2a isotype control antibodyInvitrogenCat\# 02-9688\
RRID:[AB_2532970](nif-antibody:AB_2532970){#intref0015}Armenian hamster anti-mouse TCR beta chain antibody, clone h57-597BiolegendCat\# 109229\
RRID:[AB_10933263](nif-antibody:AB_10933263){#intref0020}Donkey anti-goat IgG, polyclonal antibodyInvitrogenCat\# A-11055\
RRID:[AB_2534102](nif-antibody:AB_2534102){#intref0025}Donkey anti-rabbit IgG, polyclonal antibodyInvitrogenCat\# A-31572\
RRID: [AB_162543](nif-antibody:AB_162543){#intref0030}Donkey anti-Mouse IgM-Rhodamine Red-X-AffiniPure F(ab')2 Fragment, μ Chain Specific polyclonal antibodyJackson ImmunoResearchCat\# 715-296-020\
RRID:[AB_2340833](nif-antibody:AB_2340833){#intref0035}Goat anti-mouse Cathepsin C polyclonal antibodyR&D SystemsCat\# AF1034\
RRID:[AB_2245504](nif-antibody:AB_2245504){#intref0040}Goat anti-mouse CCL11/Eotaxin polyclonal antibodyR&D SystemsCat\# AF420\
RRID:[AB_354486](nif-antibody:AB_354486){#intref0045}Goat anti-human ENPP2/Autotaxin polyclonal antibodyR&D SystemsCat\# AF5255\
RRID:[AB_2277989](nif-antibody:AB_2277989){#intref0050}Goat anti-human/mouse Myeloperoxidase/MPO polyclonal antibodyR&D SystemsCat\# AF3667\
RRID:[AB_2250866](nif-antibody:AB_2250866){#intref0055}Mouse anti-human CD3, clone HIT3aBiolegendCat\# 300308\
RRID:[AB_314044](nif-antibody:AB_314044){#intref0060}Mouse anti-human CD3, clone OKT3BiolegendCat\# 317342\
RRID:[AB_2563410](nif-antibody:AB_2563410){#intref0065}Mouse anti-human CD14, clone HCD14BiolegendCat\# 325616\
RRID:[AB_830689](nif-antibody:AB_830689){#intref0070}Mouse anti-human CD19, clone HIB19BiolegendCat\# 302208\
RRID:[AB_314238](nif-antibody:AB_314238){#intref0075}Mouse anti-human CD19, clone HIB19BiolegendCat\# 302216\
RRID:[AB_314246](nif-antibody:AB_314246){#intref0080}Mouse anti-human CD45, clone HI30BiolegendCat\# 304044\
RRID:[AB_2563812](nif-antibody:AB_2563812){#intref0085}Mouse anti-human CD16, clone 3G8BiolegendCat\# 302015\
RRID:[AB_314215](nif-antibody:AB_314215){#intref0090}Mouse anti-human CD56, clone MEM-188BiolegendCat\# 304605\
RRID:[AB_314447](nif-antibody:AB_314447){#intref0095}Mouse anti-human CD15, clone W6D3BiolegendCat\# 323038\
RRID:[AB_2564103](nif-antibody:AB_2564103){#intref0100}Rabbit anti-mouse Gro alpha/CXCL1 antibody polyclonalAbcamCat\# ab86436\
RRID:[AB_2087574](nif-antibody:AB_2087574){#intref0105}Rabbit anti-histone H3 (Citrulline 2 + 8+ 17) polyclonal antibodyAbcamCat\# ab510 RRID:[AB_304752](nif-antibody:AB_304752){#intref0110}Rabbit anti-ISG15 polyclonal antibodyInvitrogenCat\# PA5-17461\
RRID [AB_10979338](nif-antibody:AB_10979338){#intref0115}Rat anti-mouse MHC Class II (I-A/I-E) antibody, clone M5/114.15.2InvitrogenCat\# 47-5321-82\
RRID: [AB_1548783](nif-antibody:AB_1548783){#intref0120}Rat anti-mouse/human CD11b antibody, clone M1/70BiolegendCat\# 101256\
RRID:[AB_2563648](nif-antibody:AB_2563648){#intref0125}Rat anti-mouse/human CD11b antibody, clone M1/70BiolegendCat\# 101222\
RRID:[AB_493705](nif-antibody:AB_493705){#intref0130}Rat anti-mouse CD19 antibody, clone 6D5BiolegendCat\# 115549\
RRID:[AB_2751271](nif-antibody:AB_2751271){#intref0135}Rat anti-mouse CD31 antibody, clone 390BiolegendCat\# 102421\
RRID:[AB_10613457](nif-antibody:AB_10613457){#intref0140}Rat anti-mouse CD41 antibody, clone MWReg30BiolegendCat\# 133927\
RRID:[AB_2572131](nif-antibody:AB_2572131){#intref0145}Rat anti-mouse CD44 antibody, clone IM7.8.1MiltenyiCat\# 130-102-606\
RRID:[AB_2658181](nif-antibody:AB_2658181){#intref0150}Rat anti-mouse CD45 antibody, clone 104BiolegendCat\# 109836\
RRID:[AB_2563065](nif-antibody:AB_2563065){#intref0155}Rat anti-mouse CD45 antibody, clone 104BiolegendCat\# 109824\
RRID:[AB_830789](nif-antibody:AB_830789){#intref0160}Rat anti-mouse CD55 antibody clone REA300MiltenyiCat\# 130-104-026\
RRID:[AB_2658705](nif-antibody:AB_2658705){#intref0165}Rat anti-mouse CD200 antibody, clone OX90BiolegendCat\# 123807\
RRID:[AB_2275651](nif-antibody:AB_2275651){#intref0170}Rat anti-CXCL13 antibody, clone DS8CX13ThermofisherCat\# 17-7981-82\
RRID:[AB_2762702](nif-antibody:AB_2762702){#intref0175}Rat anti-F4/80 antibody, clone BM8eBiosciencesCat\# 25-4801-82\
RRID:[AB_469653](nif-antibody:AB_469653){#intref0180}Rat anti-Ly6C antibody, clone HK1.4BiolegendCat\# 128024\
RRID:[AB_10643270](nif-antibody:AB_10643270){#intref0185}Rat anti-Ly6G antibody, clone 1A8BiolegendCat\# 127610\
RRID:[AB_1134159](nif-antibody:AB_1134159){#intref0190}Rat anti-Ly6G antibody, clone 1A8BiolegendCat\# 127627\
RRID:[AB_10897944](nif-antibody:AB_10897944){#intref0195}Rat anti-Ly6C/Ly6G purified antibody, clone RB6-8C5BiolegendCat\# 108453\
*RRID*:[AB_2616681](nif-antibody:AB_2616681){#intref0200}Rat anti-mouse CD140a antibody, clone APA5BiolegendCat\# 135905\
RRID:[AB_1953268](nif-antibody:AB_1953268){#intref0205}Rat anti-mouse Siglec-F antibody, clone E50-2440BD BiosciencesCat\# 562681\
RRID:[AB_2722581](nif-antibody:AB_2722581){#intref0210}Rat anti-mouse Ter119 antibody, clone TER-119BiolegendCat\# 116223\
RRID:[AB_2137788](nif-antibody:AB_2137788){#intref0215}Syrian hamster anti-mouse podoplanin, clone 8.1.1BiolegendCat\# 127406\
RRID:[AB_2161930](nif-antibody:AB_2161930){#intref0220}Syrian hamster anti-mouse podoplanin, clone 8.1.1BiolegendCat\# 127410\
*RRID*:[AB_10613649](nif-antibody:AB_10613649){#intref0225}Syrian hamster anti-mouse podoplanin, clone 8.1.1BiolegendCat\# 127412\
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Resource Availability {#sec4.2}
---------------------

### Lead Contact {#sec4.2.1}

Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Cecile Benezech (<cbenezec@ed.ac.uk>)

### Materials availability {#sec4.2.2}

This study did not generate new unique reagents

### Data and Code Availability {#sec4.2.3}

The accession number for the scRNaseq dataset reported in this paper is GEO: [GSM4053741](ncbi-geo:GSM4053741){#intref0315}. The authors declare that all relevant data supporting the findings of this study are available on request. R scripts for performing the main steps of analysis are available from the Lead contact on reasonable request.

Experimental Model and Subject Details {#sec4.3}
--------------------------------------

### Experimental animals {#sec4.3.1}

All experiments were conducted under a license granted by the Home Office (UK) that was approved by the University of Edinburgh or Lancaster University animal welfare and ethics review board. All individual experimental protocols were approved by a named veterinarian surgeon prior to the start of the experiment. Experiments were performed using female C57BL/6 (C57BL/6JOlaHsd) or NE deficient *Elane*^*−/−*^ mice ([@bib3]) aged 8-12 weeks. All animals were bred and maintained under specific pathogen--free conditions at the University of Edinburgh or Lancaster University Animal Facilities.

### Human subjects {#sec4.3.2}

This study was approved by the Regional Research Ethics Committee (SE. Scotland REC 02; 16/SS/0042), the University of Edinburgh/NHS Lothian ACCORD R and D Office (ref: 2016/0035) and the Office of the Caldicott Guardian, NHS Lothian (patient confidentiality advocate). Individuals were recruited after informed, signed consent was obtained. Clinical data ([Table S1](#mmc1){ref-type="supplementary-material"}) and samples were collected from patients undergoing laparoscopic surgery under general anesthesia for the following indications: biliary colic and possible or suspected appendicitis, at the Royal Infirmary of Edinburgh between 1^st^ April 2016 and 30^th^ June 2018. After the induction of anesthesia, a single tube of blood was collected into a BD Vacutainer prefilled by the manufacturer with the anticoagulant EDTA. At operation, and as soon as practical and safe after the insertion of the laparoscopic ports (to avoid iatrogenic contamination with blood), 25mL of sterile 0.154 M NaCl solution was washed into the area of interest and then aspirated using a sputum trap interposed into the surgical suction equipment. Next a 5 cm^3^ sample of omentum was resected with scissors to avoid diathermy artifact, retrieved and the sample site haemostasis ensured with diathermy. A 2 cm^2^ sample of parietal peritoneum adjacent to a port site was obtained and haemostasis ensured. Operations then continued as planned. Clinical samples were handled as follows: omentum and parietal peritoneum samples were collected into 20 mL of sterile dPBS (Sigma) within a 50ml tube. Peritoneal washings were placed into a sterile 50ml tube. All patient samples were stored on wet ice or at 4°C prior to collection from the clinical research facility and transported to the research laboratory on foot, samples collected after 5pm were processed the following day. If there were any unexpected findings at surgery, e.g., free peritoneal blood or peritoneal malignancy, patients were removed from the study and no tissue samples were taken for research purposes. There were no adverse effects due to the research study conduct.

Method Details {#sec4.4}
--------------

### Peritonitis models {#sec4.4.1}

To induce peritonitis, mice were injected intra-peritoneally with either 0.5mg Zymosan-A (Sigma) in PBS, 0.25mg of Fluorescein labeled Zymosan-A (Invitrogen), or PBS alone and samples were isolated 2-72 h later. To block NETosis, mice were injected i.p. with 400 μg/mouse of GSK484 (Cayman Chemical). Blocking antibodies against CXCL1 (Clone 48415, Invitrogen) or isotype control Rat IgG2a (Invitrogen) antibodies were injected i.p. 2 h after induction of peritonitis (40 μg/mouse). Following Zymosan and anti-CXCL1 treatment, omenta were isolated and cultured with mCherry *E. coli* ([@bib1]) or *E. coli* bioparticles (Invitrogen) *in vitro* for 5 min prior to thorough washing with RPMI-1640 (Sigma), and wholemount staining as described below.

Peritoneal exudate cells (PEC) were isolated by flushing murine peritoneal cavities with RPMI 1640 (Sigma). Murine omenta were enzymatically digested with 1mg/mL Collagenase D (Roche) for 35 min at 37°C in RPMI 1640 (Sigma) containing 1% Fetal Bovine Serum (FBS) (Sigma). Spleens were mechanically disrupted using glass slides.

### Human sample preparation {#sec4.4.2}

Human Omentum was weighed and 0.035 -- 1.8g of tissue was digested using 2mg/mL Collagenase I (Worthington) in PBS (Invitrogen/sigma) 2% Bovine Serum Albumin (BSA, Sigma), samples were disrupted using an Octolyser (Miltenyi), incubated at 37°C with intermittent shaking for 45 min, subjected to a second Octolyser dissociation step, ions were chelated by addition of EDTA (0.5M, Sigma), samples were filtered through a 100 μM filter (BD) and washed with 20ml of 2%BSA PBS prior to centrifugation at 1700pm for 10 min. The cell pellet was resuspended in 2ml of PBS 2% BSA for flow-cytometric analysis. Peritoneal wash and blood samples were centrifuged, the supernatant and serum were collected for further analysis and the cell pellet was resuspended for flow-cytometric analysis. Cell numbers and live cell count were determined using a BioRad TC20 automated cell counter and 0.4% Trypan Blue (Sigma). For the omentum *ex vivo* culture, a small piece of omentum (between 0.02 and 0.06 g) was placed in culture in 1ml of RPMI 1640 (Sigma) 10% fetal bovine serum (Sigma) 2 mM L-glutamine (Sigma) for 2 h at 37°C.

### Flow cytometry {#sec4.4.3}

Murine cells were stained with LIVE/DEAD (Invitrogen), blocked with mouse serum and anti-murine CD16/32 (clone 2.4G2, Biolegend) and stained for cell surface markers. Human samples were blocked with serum, stained for cell surface markers (See [Key Resources Table](#sec4.1){ref-type="sec"} for list of antibodies used), and DAPI (Sigma) was added to the cells prior to acquisition. All samples were acquired using a BD Fortessa and analyzed with FlowJo software (FlowJo, LLC).

### Cell-sorting and quantitative real-time PCR {#sec4.4.4}

Cells were stained for cell surface marker and sorted using a FACS Aria Fusion directly in 350 μL RLP buffer before RNA extraction using RNeasy Plus Micro Kit (QIAGEN) according to manufacturer's instruction. Complementary DNA for mRNA analysis was synthesized from total RNA using High Capacity cDNA Reverse Transcription Kit (Applied biosystems). *Cxcl1* expression was assessed using TaqManGene Expression Assay (Mm04207460_m1) by qRT-PCR (Life Technologies) and normalized to glyceraldehyde-3-phosphate dehydrogenase (*Gapdh*, Mm9999995_g1). The *C*~t~ of *Gapdh* was subtracted from the *C*~t~ of *Cxcl1*, and the relative amount was calculated as 2^−*ΔC*^~t~. Means of triplicate reactions were represented for n = 4 biological samples per condition from two separate sorts.

### Detection of chemokines, cytokine, dDNA and LPS {#sec4.4.5}

dsDNA was detected in lavage fluid and omentum culture supernatants using the picogreen assay following the manufacturer's instructions (Invitrogen). LPS was detected in human serum, omentum culture supernatants and peritoneal lavage fluid using the ToxinSensor™ Chromogenic LAL Endotoxin Assay Kit (GenScript) following manufacturer's instructions. Human Pro-inflammatory chemokines and Human Inflammation Legendplex arrays (Biolegend) were used to detect cytokines and chemokines following the manufacturer's instructions. For the heatmap representation in [Figure 7](#fig7){ref-type="fig"}C, original values were scaled between 0 and the maximum value detected for each cytokine and presented as a fraction of maximum secretion. Murine samples of omentum, mesenteries, parietal wall, diaphragm and liver were placed in culture for 2 h in 300 μL RPMI containing 10% FBS (Sigma) and 1% L-glutamine (Sigma). The quantity of murine CXCL1, CCL2 and CXCL10 present within cell culture supernatants was determined using a mix and match mouse pro-inflammatory chemokine Legendplex array (Biolegend) following the manufacturer's instructions.

### Immunofluorescence staining and microscopy {#sec4.4.6}

Human and mouse omentum samples were fixed for one h on ice in 10% NBF (Sigma) and then permeabilized in PBS 1% Triton X-100 (Sigma) for 20 min at room temperature prior to staining with primary antibodies for one h at room temperature in PBS 0.5% BSA 0.5% Triton. After washing in PBS, tissues were stained with secondary antibodies for one h at room temperature in PBS 0.5% BSA 0.5% Triton. For extra-cellular DNA staining, human omental tissues were first stained with SYTOX Blue (Invitrogen) 1 in 5000 in RPMI 1640 (Sigma) for 30 min at room temperature, washed in RPMI and then fixed in 10% NBF (Sigma) prior to permeabilization and staining. Antibodies used are listed in [Key Resources Table](#sec4.1){ref-type="sec"}. After mounting with Fluoromount G (Thermofisher), confocal images were acquired using a Leica TCS SP5 or TCS SP8 laser scanning confocal microscope. Image analysis was performed using Fiji and 3D reconstruction was created using LAS-X-3D (Leica). The mean gray value of MPO, Ly6G, CitH3 and mCherry *E. coli* was calculated inside a perimeter delimited manually as the border of the cluster. To calculate FALC volume, we manually assessed the maximum length, width and depth (z) of the clusters visualized with DAPI using 10x objective while scanning on SP5 confocal microscope. To calculate the area of FALCs covered by *E. coli,* the perimeter of the FALC was delimited manually and a fixed threshold for *E.coli* fluorescence was set. The number of CitH3^+^ nuclei and *E. coli* bioparticles was calculated using the "analyse particles" function of Fiji. The large picture of the omentum was taken as stack on a Zeiss Axio Observer Z1, deconvolved using the SVI Huygens 19.0 software and processed in Fiji first using the Maximum Intensity Projection and then stitched using Grid/Collection stitching ([@bib43]).

### Droplet based scRNaseq and data pre-processing {#sec4.4.7}

Immediately post-sorting, DAPI^-^CD45^-^Ter119^-^CD41^-^CD31^-^ stromal cell pooled from the omenta from three naive mice were run on the 10X chromium (10X Genomics) and then through library preparation following the recommended protocol for the Chromium Single Cell 3′ Reagent Kit (v2). Libraries were run on the NovaSeq S1for Illumina sequencing. Sequence reads were processed using the Cell Ranger v3.0.2 Single-Cell Software Suite from 10x Genomics. Reads were aligned to the mm10 mouse references genome (Ensembl 93). As a quality control step, genes were excluded if they were expressed in fewer than three cells. Cells were excluded on a number of criteria: those with fewer than 300 genes (n = 13), those with fewer than 300 or greater than 16000 UMIs (n = 21) or those with mitochondrial gene proportion of over 20% of total UMI counts (n = 14). A global normalization was performed where gene expression was normalized for each cell based on its total expression before being multiplied by a scale factor of 10,000 and log transformed. Variation in the UMI counts of each cell was regressed using a linear regression. Residuals from this model were centered and scaled by subtracting the average expression of each gene followed by dividing by the standard deviation of each gene. A list of 2000 variable genes were generated using the 'vst' method of the *FindVariableFeatures* function from the *Seurat* R package version 3.1.1 ([@bib49]). We obtained the transcriptional profile of 4,501 cells that passed quality control and filtering, for which we measured a median of 2,214 genes per cell.

### scRNaseq data analysis and visualization {#sec4.4.8}

Dimensionality reduction, unsupervised clustering and differential gene expression were performed using *Seurat.* We used between 1 and 10 principal components for shared nearest neighbor (SNN) clustering, as determined by the dataset variability shown in the principle component analysis (PCA). The resolution parameter was optimized based on the number of resulting clusters. Clusters were initially categorised into cell lineages based on expression of known marker genes. Clusters annotated as endothelial (*Pecam1, Cdh5*), immune (*Ptprc*), proliferating (*Mki67, Pcna, Top2a*) or those with a median number of genes per cell below 1000 were excluded from further analysis. The final dataset contained 3,838 cells measuring a median of 2,249 genes per cell. Variable features and scaled expression were re-calculated for the refined dataset, followed by dimensionality reduction and re-clustering using the same methodology described above. Differential gene expression analysis was conducted using the *FindAllMarkers* function of *Seurat* and a Wilcox rank sum test ([Table S3](#mmc2){ref-type="supplementary-material"}). Only genes with at least a 0.25 log-fold change and expressed in at least 25% of the cells in the cluster under comparison were evaluated. The *FindMarkers* function was used for direct cluster-to-cluster comparison using the same statistical model and thresholds. Cluster similarity was assessed using the *BuildClusterTree* function of *Seurat*. All violin plots, UMAP visualizations and heatmaps were generated using functions from *Seurat, ggplot2, pheatmap, and grid* R packages. UMAPs were constructed using the same number of principle components as the corresponding clustering. Heatmaps were generated using scaled expression and their range was clipped from −2.5 to 2.5. DEGs from each cluster were used for pathway analysis using Bioreactome ([@bib15])

### Mesothelium trajectory inference {#sec4.4.9}

We generated a subset of the data including clusters "*Cxcl13*^*+*^ mesothelium," "*Ifit*^*+*^ mesothelium," and "Mesothelium," re-scaled the expression data, and performed PCA analysis followed by pseudotime analysis in *slingshot* ([@bib48]). Lineage inference was performed using a cluster-based minimum spanning tree on PCs 1:10, specifying "Mesothelium" as the starting cluster. Pseudotime values thus generated were mapped to the previously generated UMAP for visualization. Variable genes of the subsetted data were then regressed on the resulting pseudotime variables using a general additive model to identify those genes that are differentially expressed across pseudotime. Cubic smoothing spline curves were fitted to the scaled expression of a selection of the top 50 differentially expressed genes (*p* value \< 1e-16) along the pseudotemporal trajectory using the *smooth.spline* (df = 3) command from the R *stats* package. These results were plotted as a heatmap with the range clipped from −2 to 2.

### Mapping mesenteric single cell data {#sec4.4.10}

The processed single cell mesenteric dataset was downloaded from GEO: [GSE102665](ncbi-geo:GSE102665){#intref0325} ([@bib23]). Cell filtering, normalization and dimensionality reduction from the omentum scRNaseq data analysis (as above) were replicated on the mesenteric scRNaseq data. *Pdgfra*^*+*^*Pdpn*^*-*^ and *Pdgfra*^*+*^*Pdpn*^*+*^ clusters were identified, isolated and mapped individually to the omentum dataset using *Scmap* version 1.8.0 ([@bib22]), following instructions given in the package vignette for feature selection and indexing of the omentum data, and cluster mapping.

### RNaseq data analysis {#sec4.4.11}

RNaseq data for epididymal adipose mesothelial cells was downloaded from GEO: [GSM3754627](ncbi-geo:GSM3754627){#intref0330}, [GSM3754628](ncbi-geo:GSM3754628){#intref0335}, [GSM3754629](ncbi-geo:GSM3754629){#intref0340}. RNaseq data for omentum mesothelial cells was downloaded from GEO: [GSM3754642](ncbi-geo:GSM3754642){#intref0345}, [GSM3754643](ncbi-geo:GSM3754643){#intref0350}, [GSM3754644](ncbi-geo:GSM3754644){#intref0355} ([@bib8]). We used *Salmon* version 0.14.1 ([@bib40]) to align and quantify transcripts to the GRCm38 reference transcriptome (ensemble 81) with "validateMappings," "seqBias," and "gcBias" options enabled. This data was imported into R using the *tximeta* package (citation), and genes with a count level of 1 or less were removed. *DESeq2* ([@bib28]) was used to perform differential gene expression analysis between the omentum and epididymal samples with an adjusted *p* value cutoff set to 0.05 for a log fold change threshold of 0. Log-fold change shrinking was performed using the *apeglm* method ([@bib51]) before plotting a volcano plot in *EnhancedVolcano* version 1.4.0 ([@bib6]) where y axis (-log~10~ adjusted P) were clipped to 50.

Quantification and Statistical Analysis {#sec4.5}
---------------------------------------

No randomization and no blinding was used for the animal experiments. Whenever possible, the investigator was partially blinded for assessing the outcome (bacterial binding). All data were analyzed using Prism 7 (GraphPad Prism, La Jolla, CA). Statistical tests performed, sample size and number of repetitions for each dataset, are described within the relevant figure legend.
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Document S1. Figures S1--S7 and Tables S1 and S2Table S3List of DEGs (Omentum scRNA-Seq Data), Related to Figure 1 Differentially expressed genes were identified as genes with a 0.25 log-fold change and expressed in at least 25% of the cells in the cluster under comparison for each cluster.Table S4List of DEGs between Omentum Mesothelium and Epidydimal Fat Pad Mesothelium, Related to Figure 1 Differentially expressed genes were identified as genes with an adjusted p value cutoff set to 0.05 for a log-fold change threshold of 0 ([@bib8]).Table S5List of DEGs between *Cxcl13*^*+*^ Mesothelium and Mesothelium (Omentum scRNA-Seq Data), Related to Figure 1 Differentially expressed genes were identified as genes with a 0.25 log-fold change and expressed in at least 25% of the cells in the cluster.Document S2. Article plus Supplemental Information
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